At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 153 target
Drug / intervention
ZG005 +1 moredrug
Likely dose
ZG005 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating ZG005 and Gecacitinib for Advanced Solid Tumor. Not yet recruiting, targeting 153 participants across 1 site.
Detailed Summary
This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet Recruiting
202620272028
First PostedAug 2025
Enrollment StartSep 2025
TodayJul 2026
Primary CompletionOct 2027
Study CompletionDec 2027
First PostedAug 27, 2025
Enrollment StartSep 1, 2025
Primary CompletionOct 1, 2027
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 10 months agoPrimary completion in 1.3 years
Interventions
ZG005drug
ZG005 20mg/kg; once every 3 weeks；IV infusion
Gecacitinibdrug
Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.